Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Maxim Group Reiterates Buy Rating and $14 PT on Mesoblast Limited (MESO); 'Locking the Database Up for Interim Analysis'
-
Maxim Group Upgrades Vertex (VRTX) to Buy
-
Maxim Group Reiterates Buy Rating and $11 PT on Intec Phara (NTEC); 'Ph3 Accordian Study Unfolding as Planned'
-
Maxim Group Reiterates Buy Rating and $22 PT on Omeros (OMER) Following Positive OMS721 Phase 2 Trial Data
-
Maxim Group Reiterates Buy Rating and $11 PT on AEterna Zentaris (AEZS) Following News of Macrilen NDA in 3Q17
-
Brainstorm Cell Therapeutics (BCLI) PT Raised to $8 at Maxim Group
-
Maxim Group Downgrades Ritter Pharmaceuticals (RTTR) to Hold
-
Maxim Group Reiterates Buy Rating and $22 PT on Omeros (OMER) Following OMS721 Positive Case Report
-
First Choice Healthcare Solutions to Present at the Microcap Conference on April 4, 2017 in New York City
-
Maxim Group Reiterates Buy and $32 PT on Zynerba Pharma (ZYNE) Following 4Q Results; 'P2 POC Data in Epilepsy Approaching in 3Q17'
-
Maxim Group Starts VistaGen Therapeutics (VTGN) at Buy
-
Maxim Group Reiterates Hold Rating on NovaBay Pharma (NBY) Following 4Q Results
-
Maxim Group Maintain Buy Rating and $9 PT on Galmed Pharma (GLMD) Following Q4 EPS Miss; 'Lack of N-T Catalysts'
-
Maxim Group Reiterates Buy Rating and $9 PT on Intec Pharma (NTEC) Following Ph1 Trial Initiation of CBD/THC Using the Accordion Delivery System
-
Interpace Diagnostics (IDXG) Enters Agreement to Restructure Debt and Terminate Royalty and Milestone Obligations
-
Interpace Diagnostics Group Announces Agreements to Successfully Restructure Debt and Terminate Royalty and Milestone Obligations
-
Maxim Group Downgrades Nimble Storage (NMBL) to Hold Following Deal With Hewlett Packard Enterprise (HPE)
-
Maxim Group Reiterates Buy Rating and $10 PT on Cytosorbents (CTSO) Following Dr. Carl June's Election to the Advisory Board
-
Maxim Group Reiterates Buy Rating and $10 PT on Adamis Pharmaceuticals (ADMP); 'Adamis Could Shine as EpiPen Falters'
-
Maxim Group Starts Dave & Buster's (PLAY) at Buy
-
Maxim Maintains Buy Rating and $10 PT on Cytosorbents (CTSO) Following Positive CytoSorb Cases to Treat HLH & CRS Relavance in Cancer Immunotherapy
-
Nephros Announces $1.2 Million Private Placement
-
Omeros Corp. (OMER) PT Raised to $22 at Maxim Group Following Strong 4Q Result; 'Omidria Gains Traction'
-
Maxim Group Reiterates Buy Rating and $5 PT on Oncosec Medical (ONCS); 'Phase 2b of IL-12 Coming in 1h17'
-
Maxim Group Reiterates Buy Rating and $110 PT on Cytosorbents (CTSO) Following Dr. Reddy Partnership
-
Trovagene (TROV) Down 20% Following Q4 EPS Miss, Multiple Downgrades
-
AEterna Zentaris (AEZS) PT Raised to $11 at Maxim Group; 'Zoptrex & Macrilen Could be Transformative'
-
Maxim Group Downgrades TrovaGene (TROV) to Hold
-
Maxim Group Upgrades Inovio Pharmaceuticals (INO) to Buy
-
Maxim Group Reiterates Buy Rating and $14 PT on Mesoblast (MESO) Following Positive Data on Phase 2 Mesenchymal Precursor Cells Trial
-
Cerecor Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016
-
Maxim Group Reiterates Buy Rating and $32 PT on Zynerba Pharma (ZYNE) Following Complete Enrollment for Phase2 ZYN002
-
Bavarian Nordic (BAVA) PT Raised to $53 at Maxim Group on Combination Study of CV-201 & Tecentriq with Roche
-
BioLife Solutions (BLFS) PT Raised to $4 at Maxim Group Following 4Q Results; 'Media Revenue Grows'
-
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
-
Maxim Group Downgrades Virtusa (VRTU) to Hold
-
Gladstone Land (LAND) Prices 1.68M Offering of Common Stock at $11.35/Share
-
Gladstone Land Corporation Announces Pricing of Common Stock Offering
-
Maxim Group Maintains Buy Rating and $6 PT on Aeterna Zentaris (AEZS) on EMA Pediatric Committee Agreement for Macrilen
-
Maxim Group Upgrades ManTech (MANT) to Buy
-
Maxim Group Reiterates Buy Rating and $6 PT on BrainStorm Cell Therapeutics (BCLI) Following New CMO Appointment
-
Gladstone Land (LAND) Plans 1.4M Common Stock Offering
-
Gladstone Land Corporation Announces Common Stock Offering
-
OncoSec to Present at Scientific and Investment Conferences in March
-
Maxim Group Reiterates Buy Rating and $14 PT on Mesoblast (MESO) Following MSC-100IV Fast Track Designation
-
New Age Beverages Corporation Launches Aspen Pure Probiotic, The World's First Shelf-Stable Probiotic Water
-
CytoSorbents to Present at the Maxim Group - Haitong Securities Inaugural Healthcare Investor and Partnering Conference
-
Abeona Therapeutics to Present at Maxim Group LLC Biotech Investor & Partnering Conference in Shanghai
-
New Age Beverages Corporation Expands XingTea(R) Brand With Jumbo, the Largest Retailer in Chile
-
New Age Beverages Corporation Launches Shelf Stable Bucha Live Kombucha, Expands in North America

